Sarepta rose 8.5% after triggering a $100 million milestone payment to Arrowhead in its SRP-1003 DM1 trial, aided by a partial Arrowhead stake sale. Early data from SRP-1003 and its FSHD program are due H2 2025. Retail sentiment is bullish, with traders eyeing upside despite Sarepta's 83% YTD drop. Arrowhead shares gained 6.3% in 2025.